Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Equities research analysts at William Blair increased their Q3 2025 EPS estimates for shares of Verve Therapeutics in a report released on Wednesday, May 14th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.73) per share for the quarter, up from their previous estimate of ($0.75). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share. William Blair also issued estimates for Verve Therapeutics' Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.52) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.97) EPS and FY2027 earnings at ($3.36) EPS.
Other analysts have also issued research reports about the company. Wall Street Zen raised Verve Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. Guggenheim boosted their target price on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Canaccord Genuity Group boosted their target price on Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Cantor Fitzgerald raised Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Finally, HC Wainwright boosted their target price on Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, April 14th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $25.75.
Check Out Our Latest Stock Report on VERV
Verve Therapeutics Stock Down 0.5%
NASDAQ VERV traded down $0.02 on Monday, reaching $4.36. The stock had a trading volume of 1,383,381 shares, compared to its average volume of 1,859,907. The firm has a market capitalization of $388.66 million, a price-to-earnings ratio of -1.77 and a beta of 1.82. Verve Therapeutics has a 12-month low of $2.86 and a 12-month high of $9.31. The stock has a fifty day moving average price of $4.61 and a two-hundred day moving average price of $5.81.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. The company had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%.
Hedge Funds Weigh In On Verve Therapeutics
Several institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. grew its stake in shares of Verve Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock worth $101,000 after acquiring an additional 1,676 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Verve Therapeutics by 1.9% in the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock worth $627,000 after acquiring an additional 2,093 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Verve Therapeutics by 15.8% in the fourth quarter. Arizona State Retirement System now owns 19,593 shares of the company's stock worth $111,000 after acquiring an additional 2,669 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in shares of Verve Therapeutics by 11.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 26,690 shares of the company's stock worth $122,000 after acquiring an additional 2,690 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Verve Therapeutics by 5.8% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company's stock worth $313,000 after acquiring an additional 2,742 shares in the last quarter. Institutional investors and hedge funds own 97.11% of the company's stock.
About Verve Therapeutics
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Further Reading
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
